-
Report: Specialty pharmacy to account for half of all prescription revenue by 2018
PHILADELPHIA — Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report released Tuesday.
-
Teva approved for new dose of Copaxone
JERUSALEM — Teva Pharmaceutical Industries on Tuesday announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL. Daily Copaxone in 20mg/mL dosage will continue to be available.
Copaxone is administered to patients with relapsing forms of multiple sclerosis. The new formulation will allow for a less frequent dosing regimen.